$CRKN
Crown Electrokinetics Corp. Stock $crkn

$crkn Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023070684 Filed on August 25, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue		$37.00K	$0.00
YoY Change
Cost Of Revenue		$23.00K
YoY Change
Gross Profit		$14.00K
YoY Change
Gross Profit Margin		37.84%
Selling, General & Admin	$2.941M	$4.409M	$3.002M
YoY Change	36.16%	46.87%	-39.49%
% of Gross Profit		31492.86%
Research & Development	$492.0K	$490.0K	$1.473M
YoY Change	-48.48%	-66.73%	238.62%
% of Gross Profit		3500.0%
Depreciation & Amortization	$100.0K	$192.0K	$68.00K
YoY Change	44.93%	182.35%	257.89%
% of Gross Profit		1371.43%
Operating Expenses	$3.433M	$4.899M	$4.475M
YoY Change	10.21%	9.47%	-17.07%
Operating Profit	-$3.433M	-$4.885M	-$4.475M
YoY Change	10.21%	9.16%	-17.07%
Interest Expense	$2.445M	$2.508M	$2.000K
YoY Change	244400.0%	125300.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	$574.0K	-$9.634M	-$2.000K
YoY Change	-57500.0%	481600.0%	0.0%
Pretax Income	-$2.859M	-$14.52M	-$4.477M
YoY Change	-8.25%	224.3%	-17.06%
Income Tax
% Of Pretax Income
Net Earnings	-$2.859M	-$14.52M	-$4.477M
YoY Change	-8.25%	224.3%	-17.06%
Net Earnings / Revenue		-39240.54%
Basic Earnings Per Share	-$0.94	-$2.720K	-$0.27
Diluted Earnings Per Share	-$0.94	-$18.02	-$0.27
COMMON SHARES
Basic Shares Outstanding	3.019M shares	50.71M shares	273.8K shares
Diluted Shares Outstanding	3.349M shares	811.0K shares	16.42M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.060M	$36.00K	$984.0K
YoY Change	502.34%	-96.34%	-92.11%
Cash & Equivalents	$2.056M	$36.00K	$984.0K
Short-Term Investments
Other Short-Term Assets	$96.00K	$36.00K	$683.0K
YoY Change	-74.74%	-94.73%	167.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$2.662M	$792.0K	$1.667M
YoY Change	268.7%	-52.49%	-86.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.638M	$2.366M	$1.092M
YoY Change	86.3%	116.67%	297.09%
Goodwill	$652.0K	$652.0K
YoY Change
Intangibles	$1.633M	$1.688M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$33.00K	$33.00K	$403.0K
YoY Change	-91.81%	-91.81%	1289.66%
Total Long-Term Assets	$9.504M	$11.36M	$5.301M
YoY Change	74.58%	114.2%	177.98%
TOTAL ASSETS
Total Short-Term Assets	$2.662M	$792.0K	$1.667M
Total Long-Term Assets	$9.504M	$11.36M	$5.301M
Total Assets	$12.17M	$12.15M	$6.968M
YoY Change	97.31%	74.33%	-52.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.855M	$1.822M	$840.0K
YoY Change	53.18%	116.9%	161.68%
Accrued Expenses	$175.0K	$408.0K	$116.0K
YoY Change	31.58%	251.72%	11.54%
Deferred Revenue
YoY Change
Short-Term Debt	$90.00K	$1.800M	$8.000K
YoY Change	1025.0%	22400.0%	-98.18%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.537M	$7.235M	$2.400M
YoY Change	58.07%	201.46%	177.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$360.0K	$355.0K	$1.815M
YoY Change	-80.17%	-80.44%
Total Long-Term Liabilities	$360.0K	$355.0K	$1.815M
YoY Change	-80.17%	-80.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.537M	$7.235M	$2.400M
Total Long-Term Liabilities	$360.0K	$355.0K	$1.815M
Total Liabilities	$2.892M	$7.590M	$4.215M
YoY Change	-15.44%	80.07%	387.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$107.7M	-$104.8M	-$82.74M
YoY Change	25.45%	26.7%
Common Stock	$7.000K	$6.000K	$1.000K
YoY Change	250.0%	500.0%
Preferred Stock		$700.0K
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.274M	$4.557M	$2.753M
YoY Change
Total Liabilities & Shareholders Equity	$12.17M	$12.15M	$6.968M
YoY Change	97.31%	74.33%	-52.4%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$2.859M	-$14.52M	-$4.477M
YoY Change	-8.25%	224.3%	-17.06%
Depreciation, Depletion And Amortization	$100.0K	$192.0K	$68.00K
YoY Change	44.93%	182.35%	257.89%
Cash From Operating Activities	-$3.420M	-$3.658M	-$2.391M
YoY Change	62.39%	52.99%	-12.67%
INVESTING ACTIVITIES
Capital Expenditures	$370.0K	$267.0K	-$254.0K
YoY Change	-1950.0%	-205.12%	198.82%
Acquisitions
YoY Change
Other Investing Activities	-$10.00K	$6.000K
YoY Change
Cash From Investing Activities	-$380.0K	-$271.0K	-$254.0K
YoY Change	1800.0%	6.69%	198.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.820M	1.824M	1.116M
YoY Change	292.18%	63.44%	27800.0%
NET CHANGE
Cash From Operating Activities	-3.420M	-3.658M	-2.391M
Cash From Investing Activities	-380.0K	-271.0K	-254.0K
Cash From Financing Activities	5.820M	1.824M	1.116M
Net Change In Cash	2.020M	-2.105M	-1.529M
YoY Change	-414.64%	37.67%	-45.76%
FREE CASH FLOW
Cash From Operating Activities	-$3.420M	-$3.658M	-$2.391M
Capital Expenditures	$370.0K	$267.0K	-$254.0K
Free Cash Flow	-$3.790M	-$3.925M	-$2.137M
YoY Change	81.69%	83.67%	-19.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q2	crkn	Series A Preferred Stock SeriesAPreferredStock		usd
CY2022Q4	crkn	Series A Preferred Stock SeriesAPreferredStock		usd
CY2023Q2	crkn	Series B Preferred Stock Value SeriesBPreferredStockValue		usd
CY2022Q4	crkn	Series B Preferred Stock Value SeriesBPreferredStockValue		usd
CY2023Q2	crkn	Series C Preferred Stock Value SeriesCPreferredStockValue		usd
CY2022Q4	crkn	Series C Preferred Stock Value SeriesCPreferredStockValue		usd
CY2023Q2	crkn	Series D Preferred Stock SeriesDPreferredStock		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-232426
	dei	Entity Registrant Name EntityRegistrantName	Crown Electrokinetics Corp.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5423944
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1110 NE Circle Blvd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Corvallis
	dei	Entity Address State Or Province EntityAddressStateOrProvince	OR
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	97330
	dei	City Area Code CityAreaCode	213
	dei	Local Phone Number LocalPhoneNumber	660.4250
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3018533	shares
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	CRKN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	us-gaap	Cash Cash	36000	usd
CY2022Q4	us-gaap	Cash Cash	821000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	756000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	590000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	792000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1411000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2366000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1409000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1688000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1598000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	797000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1842000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	652000	usd
CY2023Q2	us-gaap	Deferred Costs DeferredCosts	5819000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	150000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	180000	usd
CY2023Q2	us-gaap	Assets Assets	12147000	usd
CY2022Q4	us-gaap	Assets Assets	6590000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1822000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	865000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	408000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	621000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	484000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	574000	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	2721000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	972000	usd
CY2023Q2	crkn	Notes Payable At Fair Value NotesPayableAtFairValue	1470000	usd
CY2022Q4	crkn	Notes Payable At Fair Value NotesPayableAtFairValue	1654000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	330000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	8000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7235000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4694000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	355000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1366000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	7590000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6060000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1067341	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	337392	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109381000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88533000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104830000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88005000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4557000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	530000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12147000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6590000	usd
CY2023Q2	us-gaap	Revenues Revenues	37000	usd
	us-gaap	Revenues Revenues	59000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	23000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	54000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	14000	usd
	us-gaap	Gross Profit GrossProfit	5000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	490000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1473000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1031000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2568000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4409000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3002000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7985000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6474000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	4899000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4475000	usd
	us-gaap	Operating Expenses OperatingExpenses	9016000	usd
	us-gaap	Operating Expenses OperatingExpenses	9042000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4885000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4475000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9011000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9042000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	2508000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	2000	usd
	us-gaap	Interest Expense InterestExpense	4525000	usd
	us-gaap	Interest Expense InterestExpense	5000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-504000	usd
CY2023Q2	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	2345000	usd
	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	2345000	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	64000	usd
CY2023Q2	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	2130000	usd
	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	7736000	usd
CY2023Q2	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	-6883000	usd
	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	-7000000	usd
CY2023Q2	us-gaap	Other Expenses OtherExpenses	28000	usd
	us-gaap	Other Expenses OtherExpenses	1234000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9634000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7808000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14519000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4477000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16819000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9047000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-14519000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4477000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16819000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9047000	usd
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	6000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14616000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4477000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16997000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9047000	usd
CY2023Q2	us-gaap	Basic Earnings Per Share Adjustment Pro Forma BasicEarningsPerShareAdjustmentProForma	-18.02
CY2022Q2	us-gaap	Basic Earnings Per Share Adjustment Pro Forma BasicEarningsPerShareAdjustmentProForma	-16.35
	us-gaap	Basic Earnings Per Share Adjustment Pro Forma BasicEarningsPerShareAdjustmentProForma	-25.96
	us-gaap	Basic Earnings Per Share Adjustment Pro Forma BasicEarningsPerShareAdjustmentProForma	-33.62
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	810983	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	273767	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	653848	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	269094	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	530000	usd
	crkn	Exercise Of Common Stock Warrants ExerciseOfCommonStockWarrants	2062000	usd
	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes1 IssuanceOfCommonStockInConnectionWithConversionOfNotes1	516000	usd
	crkn	Stock Issue Duringperiod Value Issuance Of Common Stock Atthemarket Offering Net Of Offering Costs StockIssueDuringperiodValueIssuanceOfCommonStockAtthemarketOfferingNetOfOfferingCosts	2107000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4350000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	298000	usd
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1000	usd
	crkn	Issuance Of Common Stock In Connection With Conversion Of October Notes IssuanceOfCommonStockInConnectionWithConversionOfOctoberNotes	2166000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	450000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1276000	usd
	crkn	Stock Issued During Period Value Issuance Of Series F Preferred Stock In Connection With Secured Promissory Note Exchange Agre StockIssuedDuringPeriodValueIssuanceOfSeriesFPreferredStockInConnectionWithSecuredPromissoryNoteExchangeAgre	82000	usd
	crkn	Stock Issued During Period Value Issuance Of Series F1 Preferred Stock StockIssuedDuringPeriodValueIssuanceOfSeriesF1PreferredStock	1372000	usd
	crkn	Stock Issued During Period Value Issuance Of Series F2 Preferred Stock StockIssuedDuringPeriodValueIssuanceOfSeriesF2PreferredStock	464000	usd
	crkn	Stock Issued During Period Value January Notes Common Stock Commitment Share Issuance StockIssuedDuringPeriodValueJanuaryNotesCommonStockCommitmentShareIssuance	2410000	usd
	crkn	Stock Issued During Period Value Loc Common Stock Commitment Shares Issuance April2023 StockIssuedDuringPeriodValueLOCCommonStockCommitmentSharesIssuanceApril2023	230000	usd
	crkn	Stock Issued During Period Value Loc Notes Draw Down StockIssuedDuringPeriodValueLOCNotesDrawDown	3363000	usd
	crkn	Stock Issued Durign Period Commitment To Issue Shares Of Common Stock In Connection With Demand Notes StockIssuedDurignPeriodCommitmentToIssueSharesOfCommonStockInConnectionWithDemandNotes	286000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	313000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16819000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4557000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8988000	usd
	crkn	Stock Issue Duringperiod Value Issuance Of Common Stock Atthemarket Offering Net Of Offering Costs StockIssueDuringperiodValueIssuanceOfCommonStockAtthemarketOfferingNetOfOfferingCosts	58000	usd
	crkn	Exercise Of Common Stock Warrants ExerciseOfCommonStockWarrants	223000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2531000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9047000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2753000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7744000	usd
CY2023Q2	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1000	usd
CY2023Q2	crkn	Issuance Of Common Stock In Connection With Conversion Of October Notes IssuanceOfCommonStockInConnectionWithConversionOfOctoberNotes	2166000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	450000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1276000	usd
CY2023Q2	crkn	Stock Issued During Period Value Issuance Of Series F Preferred Stock In Connection With Secured Promissory Note Exchange Agre StockIssuedDuringPeriodValueIssuanceOfSeriesFPreferredStockInConnectionWithSecuredPromissoryNoteExchangeAgre	82000	usd
CY2023Q2	crkn	Stock Issued During Period Value Issuance Of Series F1 Preferred Stock StockIssuedDuringPeriodValueIssuanceOfSeriesF1PreferredStock	1372000	usd
CY2022Q2	crkn	Stock Issued During The Period Preferred Stock And Warrants Net Of Fees Value StockIssuedDuringThePeriodPreferredStockAndWarrantsNetOfFeesValue	464000	usd
CY2023Q2	crkn	Stock Issued During Period Value January Notes Common Stock Commitment Share Issuance StockIssuedDuringPeriodValueJanuaryNotesCommonStockCommitmentShareIssuance	2410000	usd
CY2023Q2	crkn	Stock Issued During Period Value Loc Common Stock Commitment Shares Issuance April2023 StockIssuedDuringPeriodValueLOCCommonStockCommitmentSharesIssuanceApril2023	230000	usd
CY2023Q2	crkn	Stock Issued During Period Value Loc Notes Draw Down StockIssuedDuringPeriodValueLOCNotesDrawDown	3363000	usd
CY2023Q2	crkn	Stock Issued Durign Period Commitment To Issue Shares Of Common Stock In Connection With Demand Notes StockIssuedDurignPeriodCommitmentToIssueSharesOfCommonStockInConnectionWithDemandNotes	286000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	132000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-14519000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4557000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	5724000	usd
CY2022Q2	crkn	Stock Issue Duringperiod Value Issuance Of Common Stock Atthemarket Offering Net Of Offering Costs StockIssueDuringperiodValueIssuanceOfCommonStockAtthemarketOfferingNetOfOfferingCosts	58000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1448000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4477000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2753000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16819000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9047000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	313000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2531000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	372000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	234000	usd
	crkn	Loss On Extinguishment Of Warrant Liabilitys LossOnExtinguishmentOfWarrantLiabilitys	-504000	usd
	crkn	Chang In Fair Value Of Derivative Liability ChangInFairValueOfDerivativeLiability	7736000	usd
	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax	2345000	usd
	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes	-7000000	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-4049000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1045000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	239000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	1275000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-235000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-52000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	886000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	370000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-742000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-182000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1101000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-143000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8388000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5943000	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	644000	usd
	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	707000	usd
	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	258000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	61000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1351000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-319000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2061000	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	2198000	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	60000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2350000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	91000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1058000	usd
	crkn	Proceeds From Issuance Of Series F1 Preferred Stock Net Of Fees ProceedsFromIssuanceOfSeriesF1PreferredStockNetOfFees	2328000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	748000	usd
	crkn	Proceeds From Issuance Of Promissory Notes ProceedsFromIssuanceOfPromissoryNotes	1357000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1997000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8954000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1116000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-785000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5146000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	821000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6130000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	984000	usd
	crkn	Issuance Of Series E Preferred Stock In Connection With Loc IssuanceOfSeriesEPreferredStockInConnectionWithLOC	9943000	usd
	us-gaap	Stock Issued1 StockIssued1	450000	usd
	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes IssuanceOfCommonStockInConnectionWithConversionOfNotes	516000	usd
	crkn	Issuance Of Common Stock Warrants In Connection With Consideration Payable IssuanceOfCommonStockWarrantsInConnectionWithConsiderationPayable	223000	usd
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	6000	usd
	crkn	Commitment To Issue Shares Of Common Stock In Connection With Demand Notes CommitmentToIssueSharesOfCommonStockInConnectionWithDemandNotes	286000	usd
	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable	92000	usd
	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable	112000	usd
	us-gaap	Interest Paid Net InterestPaidNet	8000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3000	usd
CY2023Q2	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	8.868
CY2023Q2	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	8.994
CY2023Q2	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	9.228
CY2023Q1	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	650000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
	crkn	Accumulated Deficit AccumulatedDeficit	104800000	usd
CY2023Q2	crkn	Working Capital WorkingCapital	6400000	usd
	us-gaap	Net Income Loss Allocated To General Partners NetIncomeLossAllocatedToGeneralPartners	17000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	8400000	usd
	us-gaap	Debt Instrument Sinking Fund Payment DebtInstrumentSinkingFundPayment	10000000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	100000000	usd
	us-gaap	Line Of Credit Assumed1 LineOfCreditAssumed1	50000000	usd
CY2023Q2	crkn	Aggregate Gross Proceed Percentage AggregateGrossProceedPercentage	0.03	pure
	crkn	Agreement Of Sale AgreementOfSale	2100000	usd
CY2023Q3	crkn	Placement Shares Amount PlacementSharesAmount	5100000	usd
CY2023Q3	crkn	Aggregate Gross Proceed Percentage AggregateGrossProceedPercentage	0.03	pure
CY2023Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	545100	shares
CY2023Q2	crkn	Weighted Average Price Per Share WeightedAveragePricePerShare	3.05
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2000000	usd
CY2023Q2	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.15	pure
CY2023Q2	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	200000	usd
CY2023Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	2100000	usd
CY2023Q2	us-gaap	Secured Demand Notes SecuredDemandNotes	76626000000	usd
CY2023Q2	us-gaap	Debt Instrument Repurchased Face Amount DebtInstrumentRepurchasedFaceAmount	140804	usd
CY2023Q2	crkn	Aggregate Shares1 AggregateShares1	46935	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	592129	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	124946	shares
CY2023Q2	crkn	Exercise Price Per Share ExercisePricePerShare	9.228	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the valuation of its business combination, senior secured convertible notes and warrants, Series F/F-1/F-2 Preferred Stock, warrants, and equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted the new revenue standard, ASC 606, on March 31, 2019 using the full retrospective approach. The adoption did not have an effect on 2021 or 2020 revenue recognition or a cumulative effect on opening equity, as the timing and measurement of revenue recognition is materially the same as under ASC 605. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Step 1: Identify the contract with the customer</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Step 2: Identify the performance obligations in the contract</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Step 3: Determine the transaction price</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s performance obligation is to provide fiber splicing services as required based on short-term work orders as work is assigned by the Customer. The Company is required to complete the description of work described in the work order and test the service provided prior to any recognition of revenue and invoicing. The short-term work orders are for very specific performance obligations which are performed from start to finish within two weeks or less, and more often, within one week. The Company is required to adhere to the rules and regulations that are outlined in the Agreement between the Company and the Customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost for the work performed is outlined in the individual work orders based on the detailed description of work to be performed. All of the revenue is recognized immediately upon completion of the work in each work order. A 5% retainage will be withheld by the Customer upon payment of invoices and will be paid to the Company within one year after termination of the contract. The retainage can be utilized by Customer for any claims that may arise after work is completed up through one year after completion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue recognized during the six months ended June 30, 2023 was generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was immaterial. No revenue was recognized by the Company during the six months ended June 30, 2022.</p>
	crkn	Percentage Of Payment Invoices PercentageOfPaymentInvoices	0.05	pure
	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	300000	usd
	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	100000	usd
CY2023Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	31724	shares
CY2023Q1	crkn	Converted Minimum Price Per Share ConvertedMinimumPricePerShare	9.42
	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	300000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	409000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	621000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4632314	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	285667	shares
CY2023Q1	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	650000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Number Of Employees DefinedContributionPlanNumberOfEmployees	12	pure
CY2023Q1	crkn	Asset Acquisition Term AssetAcquisitionTerm	P1Y
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	655000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	200000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	5000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	529000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	338000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	7000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	652000	usd
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	645000	usd
CY2022Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	5400000	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	362657	shares
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.54	pure
CY2022Q4	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.35	pure
	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	215000	usd
CY2022	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	300000	usd
	us-gaap	Professional Fees ProfessionalFees	385000	usd
	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	34000	usd
CY2022	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	142000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	36000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	63000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	756000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	590000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3076000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1871000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	710000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	462000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	2366000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	1409000	usd
CY2023Q2	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	100000	usd
CY2022Q2	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	100000	usd
CY2023Q2	crkn	Finite Lived Intangible Assets Patents Gross FiniteLivedIntangibleAssetsPatentsGross	1800000	usd
CY2022Q4	crkn	Finite Lived Intangible Assets Patents Gross FiniteLivedIntangibleAssetsPatentsGross	1800000	usd
CY2023Q2	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2022Q4	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2023Q2	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	200000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2375000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2175000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-687000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-577000	usd
CY2023Q2	crkn	Finite Lived Intangible Assets Accumulated Research License Net FiniteLivedIntangibleAssetsAccumulatedResearchLicenseNet	1688000	usd
CY2022Q4	crkn	Finite Lived Intangible Assets Accumulated Research License Net FiniteLivedIntangibleAssetsAccumulatedResearchLicenseNet	1598000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	121000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	235000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	234000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	197000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	901000	usd
CY2023Q2	crkn	Finite Lived Intangible Asset Net FiniteLivedIntangibleAssetNet	1688000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	29.7
CY2022Q4	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	19.32
CY2022Q4	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P5Y
CY2023Q2	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	1500000	usd
	crkn	Standing Letterof Credit StandingLetterofCredit	150000	usd
CY2022	crkn	Standing Letterof Credit StandingLetterofCredit	223000	usd
CY2023Q2	us-gaap	Line Of Credit LineOfCredit	9943000	usd
CY2023Q2	crkn	Deferreddebtissuancecosts Deferreddebtissuancecosts	10093000	usd
CY2022Q4	crkn	Deferreddebtissuancecosts Deferreddebtissuancecosts	223000	usd
CY2023Q2	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	4274000	usd
CY2022Q4	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	73000	usd
CY2023Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	5819000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	150000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9900000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4100000	usd
	crkn	Convertible Promissory Notes ConvertiblePromissoryNotes	2400000	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1470000	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	2721000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1654000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	972000	usd
CY2023Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1600000	usd
CY2023Q1	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	maturity date of the 2022 Notes from October 19, 2023 to April 18, 2024
CY2023Q1	us-gaap	Restricted Investments Percent Of Net Assets RestrictedInvestmentsPercentOfNetAssets	0.05	pure
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.05	pure
	crkn	Shares Of Common Stock SharesOfCommonStock	248981	shares
	crkn	Fair Value Converted Notes FairValueConvertedNotes	2200000	usd
CY2023Q1	crkn	Change In Fair Value ChangeInFairValue	400000	usd
CY2023Q1	crkn	Agreement Issued AgreementIssued	2000000	usd
CY2023Q2	crkn	Withdrew Amount WithdrewAmount	400000	usd
	crkn	Fair Value Amount FairValueAmount	400000	usd
	crkn	Warrants Exercised WarrantsExercised	106764	shares
CY2022	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm	2022-12-31
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.487	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0474	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y9M18D
CY2023Q2	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	274000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	510000	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	32000	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current And Noncurrent WorkersCompensationLiabilityCurrentAndNoncurrent	104000	usd
CY2023Q2	us-gaap	Other Employee Related Liabilities Current And Noncurrent OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent	103000	usd
CY2022Q4	us-gaap	Other Employee Related Liabilities Current And Noncurrent OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent	7000	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.42
CY2023Q2	us-gaap	Shares Issued SharesIssued	161561	shares
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	83849	shares
CY2023Q2	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	1392657	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.932
CY2023Q2	us-gaap	Shares Issued SharesIssued	127393	shares
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	55242	shares
CY2023Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	200000	usd
CY2023Q2	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	1000000	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	248981	shares
CY2023Q1	us-gaap	Notes Issued1 NotesIssued1	2000000	usd
CY2023Q1	crkn	Issuance Date IssuanceDate	P60D
CY2023Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	30
CY2023Q2	us-gaap	Stock Dividends Shares StockDividendsShares	33333	shares
CY2023Q2	crkn	Accrued Interest Percentage AccruedInterestPercentage	0.15	pure
CY2023Q2	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	200000	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33333	shares
CY2023Q2	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	maturity date of the 2023 Note balance until May 15, 2023
CY2023Q2	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	700000	usd
CY2023Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	200000	usd
CY2023Q2	crkn	Accrued Interest Percentage AccruedInterestPercentage	0.15	pure
CY2023Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	150000	usd
CY2023Q2	us-gaap	Other Commitment OtherCommitment	200000000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	200000	usd
CY2023Q2	crkn	Convertible Promissory Note ConvertiblePromissoryNote	150	usd
CY2023Q2	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	600000	usd
CY2023Q2	us-gaap	Other Commitment OtherCommitment	2100000	usd
	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	maturity dates of each until July 16, 2023
CY2023Q2	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	133333	shares
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	2000000	usd
CY2023Q1	us-gaap	Senior Notes SeniorNotes	1200000	usd
CY2023Q1	crkn	Purchase Of Warrants PurchaseOfWarrants	41667	shares
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1000000	usd
CY2023Q1	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	0.10	pure
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	120000	usd
CY2023Q1	crkn	Warrant Exercise Price WarrantExercisePrice	19.32
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11833	shares
CY2023Q2	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	66667	shares
CY2023Q2	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	25000	shares
CY2023Q2	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	100000	shares
CY2023Q1	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax	2200000	usd
CY2023Q2	us-gaap	Senior Notes SeniorNotes	200000	usd
CY2023Q2	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax	100000	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	100000	usd
	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	41667	shares
CY2023Q2	us-gaap	Senior Notes SeniorNotes	1100000	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
	crkn	Common Stock Shares Outstanding Percentage CommonStockSharesOutstandingPercentage	0.1999	pure
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	2900000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Preferred Stock AdditionalPaidInCapitalPreferredStock	4350000	usd
CY2023Q2	crkn	Aggregate Principal Shares AggregatePrincipalShares	206	shares
CY2023Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	600000	usd
CY2023Q2	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	576	shares
	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	592129	shares
	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	8.868
	us-gaap	Equity Classified Written Call Option Modification Equity Issuance Increase Decrease In Equity Amount EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount	100000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	200000	usd
	crkn	Warrant Liability WarrantLiability	1200000	usd
CY2023Q2	us-gaap	Additional Paid In Capital Preferred Stock AdditionalPaidInCapitalPreferredStock	700000	usd
CY2023Q2	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	3583	shares
CY2023Q2	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	8.994
CY2023Q2	us-gaap	Preferred Stock Discount On Shares PreferredStockDiscountOnShares	0.7	usd
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	500000	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	70000	shares
	crkn	Total Number Of Outstanding Shares Percentage TotalNumberOfOutstandingSharesPercentage	0.199	pure
CY2023Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	45000	usd
CY2022Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	445000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	104000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	500000	usd
CY2023Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	87000	usd
CY2022Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1003000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	209000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	2031000	usd
CY2023Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	132000	usd
CY2022Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1448000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	313000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2531000	usd
CY2023Q2	us-gaap	Share Price SharePrice	19.3
CY2023Q1	us-gaap	Shares Issued SharesIssued	96894	shares
CY2023Q1	us-gaap	Share Price SharePrice	19.3
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	592137	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	159295	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	153.35
CY2022	crkn	Weighted Average Remaining Contractual Term Years Outstanding At Ending Balances WeightedAverageRemainingContractualTermYearsOutstandingAtEndingBalances	P6Y6M
CY2022Q4	crkn	Aggregate Intrinsic Value Outstanding At Ending Balance AggregateIntrinsicValueOutstandingAtEndingBalance	26188	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1516	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	196.86
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	157779	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	157.47
	crkn	Weighted Average Remaining Contractual Term Years Outstanding At Ending Balances WeightedAverageRemainingContractualTermYearsOutstandingAtEndingBalances	P6Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	142884	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	167.85
	crkn	Weighted Average Remaining Contractual Term Years Exercisable WeightedAverageRemainingContractualTermYearsExercisable	P5Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	10483	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	82.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	3344	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	104.04
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7139	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	71.68
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	41667	shares
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	19.3
	crkn	Granted Restricted Stock Units GrantedRestrictedStockUnits	45000	shares
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	30
CY2023Q2	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	16.67
CY2022Q4	us-gaap	Shares Issued SharesIssued	362657	shares
CY2022Q4	us-gaap	Share Price SharePrice	19.3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	106764	shares
CY2023Q2	us-gaap	Shares Issued SharesIssued	106764	shares
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	8.868
	crkn	Warrant Purchase Shares WarrantPurchaseShares	398379	shares
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	8.994
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	crkn	Warrants Issued Purchase Shares WarrantsIssuedPurchaseShares	124948	shares
	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	9.228
CY2022Q3	us-gaap	Retail Land Sales Installment Method Sales Value RetailLandSalesInstallmentMethodSalesValue	85450000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	as additional consideration for the PO’s, the Company issued a warrant to Hudson to purchase 5,000 shares of the Company’s common stock at $45.00 per share. The warrant has a five-year life and expires on August 12, 2027.
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	161700000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	161700000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	85450000	usd
CY2022Q1	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	223000000	usd
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400	usd
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200	usd
CY2017Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4500	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7550	usd
CY2022Q1	crkn	Eighth Amendmen Description EighthAmendmenDescription	the Company entered into the eighth amendment to its lease with Oregon State University which expands the lease to now include approximately 703 square feet of lab space, 768 square feet of cubicle space, 2,088 square feet of Highbay lab space, and 376 square feet of High bay storage space in a building commonly known as Building 11.
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	44252	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	41323	usd
CY2021Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q2	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	7388	usd
CY2021Q2	us-gaap	Operating Leases Of Lessor Contingent Rentals Basis Spread On Variable Rate OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate	0.03	pure
CY2021Q2	us-gaap	Deposit Assets DepositAssets	8315	usd
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2021Q4	us-gaap	Lessee Finance Lease Renewal Term1 LesseeFinanceLeaseRenewalTerm1	P62Y
CY2021Q4	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	100000	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	150000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	800000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	126000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	190000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	316000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	380000	usd
CY2023Q2	crkn	Variables Lease Cost VariablesLeaseCost	9000	usd
CY2022Q2	crkn	Variables Lease Cost VariablesLeaseCost	-11000	usd
	crkn	Variables Lease Cost VariablesLeaseCost	-49000	usd
	crkn	Variables Lease Cost VariablesLeaseCost	-16000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	117000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	201000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	365000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	396000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	119000	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	189000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	311000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	341000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2336000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	392000	usd
CY2023Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	405000	usd
CY2023Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	194000	usd
CY2023Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	100000	usd
CY2023Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9000	usd
CY2023Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1100000	usd
CY2023Q2	crkn	Operating Leases Future Minimum Payments Present Value Discount OperatingLeasesFutureMinimumPaymentsPresentValueDiscount	261000	usd
CY2023Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	839000	usd
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	200000	usd
CY2022Q2	us-gaap	Payments For Rent PaymentsForRent	200000	usd
	us-gaap	Payments For Rent PaymentsForRent	400000	usd
	us-gaap	Payments For Rent PaymentsForRent	200000	usd
CY2023Q2	us-gaap	Payments For Fees PaymentsForFees	150000	usd
CY2023Q2	crkn	Additional Deposit AdditionalDeposit	115394	usd
	crkn	Purchase Agreement PurchaseAgreement	0.97	pure
	crkn	Net Proceed NetProceed	283949	usd
CY2023Q2	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	30000.00	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	1.81
	crkn	Gross Proceeds GrossProceeds	3	usd
	crkn	Combined Additional Atm And Eloc Amount CombinedAdditionalATMAndELOCAmount	2100000	usd
	crkn	Excess Stockholder Equity Levels ExcessStockholderEquityLevels	2500000	usd
CY2022Q4	crkn	Series D Preferred Stock SeriesDPreferredStock		usd
CY2023Q2	crkn	Series E Preferred Stock SeriesEPreferredStock		usd
CY2022Q4	crkn	Series E Preferred Stock SeriesEPreferredStock		usd
CY2023Q2	crkn	Series F Preferred Stock SeriesFPreferredStock		usd
CY2023Q2	crkn	Series F1 Preferred Stock SeriesF1PreferredStock		usd
CY2023Q2	crkn	Series F2 Preferred Stock SeriesF2PreferredStock		usd
CY2022Q2	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2022Q2	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2022Q2	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
CY2022Q2	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1		usd
	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1		usd
CY2022Q2	us-gaap	Other Expenses OtherExpenses		usd
	us-gaap	Other Expenses OtherExpenses		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments		usd
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	269094	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	273767	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	653848	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	810983	shares
	crkn	Deemed Dividend For Repricing Of Series D Preferred Stock DeemedDividendForRepricingOfSeriesDPreferredStock		usd
	crkn	Loss On Extinguishment Of Warrant Liabilitys LossOnExtinguishmentOfWarrantLiabilitys		usd
	crkn	Chang In Fair Value Of Derivative Liability ChangInFairValueOfDerivativeLiability		usd
	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes		usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
	us-gaap	Interest Expense Other InterestExpenseOther		usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	crkn	Proceeds From Issuance Of Series F1 Preferred Stock Net Of Fees ProceedsFromIssuanceOfSeriesF1PreferredStockNetOfFees		usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
	crkn	Proceeds From Issuance Of Promissory Notes ProceedsFromIssuanceOfPromissoryNotes		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	crkn	Issuance Of Series E Preferred Stock In Connection With Loc IssuanceOfSeriesEPreferredStockInConnectionWithLOC		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes IssuanceOfCommonStockInConnectionWithConversionOfNotes		usd
	crkn	Issuance Of Common Stock Warrants In Connection With Consideration Payable IssuanceOfCommonStockWarrantsInConnectionWithConsiderationPayable		usd
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash		usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
CY2022	us-gaap	Professional Fees ProfessionalFees		usd
CY2022Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross		usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit		usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent		usd
CY2023Q2	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent		usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent		usd
CY2023Q2	us-gaap	Workers Compensation Liability Current And Noncurrent WorkersCompensationLiabilityCurrentAndNoncurrent		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2022	crkn	Weighted Average Remaining Contractual Term Years Outstanding At Beginning Balance WeightedAverageRemainingContractualTermYearsOutstandingAtBeginningBalance
CY2021Q4	crkn	Aggregate Intrinsic Value Outstanding At Beginning Balance AggregateIntrinsicValueOutstandingAtBeginningBalance		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	crkn	Weighted Average Remaining Contractual Term Years Granted WeightedAverageRemainingContractualTermYearsGranted
CY2022	crkn	Aggregate Intrinsic Value Granted AggregateIntrinsicValueGranted		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	crkn	Weighted Average Remaining Contractual Term Years Canceled WeightedAverageRemainingContractualTermYearsCanceled
CY2022	crkn	Aggregate Intrinsic Value Canceled AggregateIntrinsicValueCanceled		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	crkn	Weighted Average Remaining Contractual Term Years Forfeited WeightedAverageRemainingContractualTermYearsForfeited
CY2022	crkn	Aggregate Intrinsic Value Forfeited AggregateIntrinsicValueForfeited		usd
	crkn	Weighted Average Remaining Contractual Term Years Forfeited WeightedAverageRemainingContractualTermYearsForfeited
CY2023Q2	crkn	Aggregate Intrinsic Value Outstanding At Ending Balance AggregateIntrinsicValueOutstandingAtEndingBalance		usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001761696

Files In Submission

Name	View Source	Status
0001213900-23-070684-index-headers.html	Edgar Link	pending
0001213900-23-070684-index.html	Edgar Link	pending
0001213900-23-070684.txt	Edgar Link	pending
0001213900-23-070684-xbrl.zip	Edgar Link	pending
crkn-20230630.xsd	Edgar Link	pending
f10q0623ex31-1_crownelectro.htm	Edgar Link	pending
f10q0623ex31-2_crownelectro.htm	Edgar Link	pending
f10q0623ex32-1_crownelectro.htm	Edgar Link	pending
f10q0623ex32-2_crownelectro.htm	Edgar Link	pending
f10q0623_crownelectro.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
crkn-20230630_cal.xml	Edgar Link	unprocessable
crkn-20230630_pre.xml	Edgar Link	unprocessable
crkn-20230630_def.xml	Edgar Link	unprocessable
crkn-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0623_crownelectro_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRKN
Crown Electrokinetics Corp. Stock $crkn

2023 Q3 Form 10-Q Financial Statement

#000121390023070684 Filed on August 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN Crown Electrokinetics Corp. Stock $crkn

2023 Q3 Form 10-Q Financial Statement

#000121390023070684 Filed on August 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN
Crown Electrokinetics Corp. Stock $crkn